RISK OF SERIOUS INFECTIONS ASSOCIATED WITH VEDOLIZUMAB VERSUS TUMOR NECROSIS FACTOR ANTAGONISTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A MULTINATIONAL, POPULATION-BASED COHORT STUDY

Julien Kirchgesner  ¹     Rishi J Desai  ¹     Laurent Beaugerie  ²     Sebastian Schneeweiss  ²     Seoyoung C Kim  ^2    
1 Brigham and Women's Hospital and Harvard Medical School, Boston, United States
² Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France

Topic
IBD, Immunology, Paediatrics, Primary Care

Session
Special situations in IBD

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)